BioSpace News Archive

Healthcare Resource Group, Inc. is providing notice on behalf of Barlow Respiratory Hospital of an incident that may affect the security of certain personal information relating to current and former Barlow patients.

U.S. Food and Drug Administration (FDA) extends review of risdiplam by three months following submission of additional data

BiomX Inc. (the “Company”) (NYSE: PHGE), a clinical-stage company developing both natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it will hold its 2020 Annual Meeting of Stockholders (the “2020 Annual Meeting”) on June 3, 2020 at 9:00 a.m. Eastern Time.

CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the first quarter of 2020 after the market close on Wednesday, April 29, 2020.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for its review of the New Drug Application (NDA) of risdiplam with a decision expected by August 24, 2020

Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 19th Annual Needham Virtual Healthcare Conference

COLCORONA trial to examine whether colchicine can reduce complications associated with COVID-19, slow disease progression, and save patient lives

Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced orders and an increased revenue estimate for Q1 and the full year 2020.

X4 Pharmaceuticals, Inc. today hosted a virtual Analyst Day, A Deep Dive into WHIM Syndrome , the target disease of the company’s Phase 3 candidate

Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced that financial results for the first quarter of fiscal year 2020 will be released before the market opens on Monday, May 11. Management will host a